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NATuRe GeNeTIcS treatment guidelines emphasize the benefit of blood pressure-low ering strategies, including drug treatments, at lower thresholds of SBP or DBP 4 . These guidelines also identify a substantial population who are untreated or undertreated for elevated blood pressure, or do not have sufficient treatment response to antihypertensive drugs, and highlight the need to identify new gene targets for therapies 5 .
Largescale genomewide association studies (GWAS) have reported > 250 loci associated with blood pressure traits, estab lishing that blood pressure traits are complex with many genetic determinants of modest effect . Large blood pressure GWAS metaanalyses combine evidence from many cohorts and identify genetic determinants of SBP, DBP and pulse pressure levels. Regulatory effects may account for substantial heritability in GWAS, and GWAS sentinel SNPs are enriched for regulatory SNPs compared with the proportion of the genome containing regulatory elements [28] [29] [30] . Most bloodpressure SNPs are noncoding, are not in strong linkage disequilibrium (LD) with traitassociated coding variants and are found in regulatory elements 12 . Several methods have recently been developed to use multiple SNPs to perform gene based tests of association between imputed gene expression levels and phenotypes, which are tissue specific and provide interpretable direction and magnitude of effects [31] [32] [33] [34] .
In this transethnic study, we performed a metaanalysis of data for 459,777 participants, 318,891 from the Million Veteran Program (MVP) and 140,886 from the UK Biobank (UKB) 12 . We subse quently performed independent replication in 316,301 participants from the International Consortium for Blood Pressure (ICBP) 25 and Vanderbilt University's BioVU cohort to study common variant associations with minorallele frequency (MAF) > 1% ( Fig. 1 ). With 318,891 participants from the MVP as the discovery sample, we conducted two studies of rare variants, one focused on variants across the genome with independent replication in 445,360 par ticipants from UKB and the other focused on exonic regions with replication in up to 420,704 participants from the Blood Pressure-International Consortium of Exome chip studies (BPICE). We report associations between blood pressure and common and rare SNPs, and blood pressure and genetically predicted gene expression (GPGE). We also evaluated gene-drug relationships and toxicities, conducted a phenomewide association study (PheWAS) of blood pressure genetic risk scores, conducted pathway and tissue geneset enrichment analyses and performed studies to identify mouse kid ney cell types in which implicated genes were upregulated.
Results
MVP participants (n = 318,891), representing the majority of the discovery sample size, were predominantly male (91.5%) and were administratively identified as nonHispanic whites (69.1%), and nonHispanic blacks, Hispanics, nonHispanic Asians and non Hispanic Native Americans represented 18.8%, 6.7%, 0.77% and 0.85% of the population, respectively (Supplementary Table 1 ). Blacks were older on average (60.6 ± 11.4 years), followed by whites (58.9 ± 12.6 years), Native Americans (58.9 ± 12.6 years), Hispanics (52.7 ± 14.5 years) and Asians (48.6 ± 16.1 years) (mean ± s.d.). About half of the MVP participants were on antihypertensive medi cations, and a quarter had diabetes. Participants from the UKB interim release, originating from UKB application number 236, (n = 140,886), were also included in the discovery analysis; their characteristics have been reported elsewhere 12 .
Single-variant analyses. Common variants. We identified a total of 505 independent loci (201 novel loci, 304 previously reported) associated with one or more blood pressure traits: SBP, DBP and pulse pressure. Among the previously reported loci, 216 were asso ciated with SBP, 76 with DBP and 208 with pulse pressure (Table 1 ; Fig. 2a-c ; Supplementary Table 2a -c); none of these loci were evalu ated for replication. Sentinel variants from loci that were deemed to be novel (by comparison with the GWAS catalog accessed March 2017 or literature report; P < 1 × 10 −6 in the discovery phase; > 500 kb from a known sentinel SNP; r 2 ≤ 0.1 with known sentinel SNPs) and up to two proxies (n = 1,478) were carried forward for replication with the ICBP. Replicated variants had consistent direc tions of effect in the discovery and replication phases, had P < 0.05 in the replication stage and had metaanalysis (discovery and rep lication) P < 5 × 10 −8 (details in Methods). These replicated SNPs represented 201 novel loci and included 124 loci for SBP, 4 loci for DBP and 123 loci for pulse pressure ( Supplementary Table 3a -c). Comparison of mean effect estimates of blood pressure traitincreasing alleles showed that, on average, novel loci had smaller magnitudes of effect (0.24, 0.14 and 0.18 mm Hg per allele for SBP, DBP and pulse pressure, respectively) than known loci (0.32, 0.27 and 0.27 mm Hg per allele for SBP, DBP and pulse pressure, respec tively; Table 1 ). Sentinel SNPs at all independent loci from meta analysis of common variants explained 3.56%, 1.06% and 3.72% of the total variance for SBP, DBP and pulse pressure, respectively. Novel variants contributed to 0.80%, 0.24% and 0.72% of the total variance explained by all independent loci for SBP, DBP and pulse pressure, respectively.
We detected an additional 37 conditionally independent SNPs from 29 loci by using discovery metaanalysis results (seven novel, three within the boundaries of both known and novel loci) as signifi cant in one or more blood pressure traits ( Supplementary Table 4 ).
Trans-ancestry comparisons.
To update the observations reported by Franceschini et al. in 2013 (ref. 9 ), in which 29 SNP effects on blood pressure reported by Ehret et al. in 2011 (ref. 35 ) were consis tent across European, African, East Asian and South Asian ances tries, we compared known and novel loci across racial and ethnic groups in MVP. We examined the correlations between effect sizes in white, black and Hispanic samples. The observed correlations of effect sizes between race and ethnic groups in MVP were weaker than those previously reported, although directions of effects were largely consistent (Supplementary Fig. 1 ; Supplementary Table 5 ).
Rare exonic variants. Rare exonic variants (MAF < 1%) with sug gestive evidence of association (P < 1 × 10 −6 ) from the discovery sample were queried for replication in populations from BioVU (n = 17,277) and BPICE (n max = 420,704). Eighteen variants were on the exome chip and available for final metaanalysis. Ten mis sense variants from seven genes were associated with blood pres sure traits (P < 5 × 10 −8 ; Table 2 ). Five variants were associated with SBP and/or DBP (rs141325069 PDE3A; p.Arg137Gln); rs139491786, (SLC9A3R2; p.Arg60Trp), rs61760904 (RRAS; p.Asp133Asn), rs73181210 (PHC3; p.Lys745Glu) and rs3025380 (DBH; p.Gly88Ala)) with consistent directions of effect for SBP and DBP. Three rare variantsfrom COL21A1 (rs115079907 (p.Gly882Arg), rs200999181 (p.Gly665Val) and rs2764043 (p.Leu277Pro)) and one variantfrom NOX4 (rs139341533; p.Leu73Phe) were significantly associated with pulse pressure but not with SBP or DBP and had opposite directions of effect for SBP and DBP. SNPs in RRAS, DBH and one of the three SNPs in COL21A1 (rs200999181) have been previ ously reported [22] [23] [24] . Average absolute values of effect estimates for SBP, DBP and pulse pressure in these variants were 1.52, 0.63 and 1.50 mm Hg per allele, respectively.
We conditioned these SNPs on the sentinel common variant in each respective locus, where available, in the MVP discovery sample of white participants and compared effect estimates before and after conditioning. SNP rs139491786 in SLC9A3R2 showed a > 50% reduction in effect size after conditioning on common variant rs140869992 (r 2 = 0.35). Effect sizes for all other rare exonic variants were considered independent, as no substantial differences in effect estimates were observed after conditioning (Supplementary Table 6 ).
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All rare variants. Discovery analysis in the MVP samples only (excluding UKB interim release data) identified 1,684 rare variants with suggestive evidence for association across the three blood pres sure traits; 1,066 of these variants were available in UKB for metaanalysis. We observed statistically significant associations (P < 5 × 10 −8 ) between 48 rare variants and one or more blood pressure traits. We identified 40 SNPs for pulse pressure, 8 SNPs for SBP and 2 SNPs for DBP ( Supplementary Table 7 ). Average absolute values of effect estimates for SBP, DBP and pulse pressure were 9.67, 2.33 and 13.89 mm Hg per allele, respectively. The mis sense variants from NOX4 (rs139341533), SLC9A3R2 (rs139491786) and COL21A1 (rs200999181, rs2764043) were evaluated in the both the exonic and rarevariant analyses separately (Table 2 ; Supplementary Table 7) . 
Transcriptome-wide association analyses.
Known loci: known loci were tested for significance only in the discovery sample (n = 459,776). Novel loci: tested in discovery sample and ICB (n-discovery = 459,776; n-replication = 299,024; total n = 758,800) a Mean β = average and s.d. of the absolute value of β -estimates for each trait. b P from two-sample t-test comparing mean β for known loci and all novel loci. PP, pulse pressure; tier 1, first-tier significance criteria: GWAS significance at discovery and replication passing Bonferroni threshold, consistent directions of associations between discovery and replication sets, and GWAS significant at final meta-analysis; tier 2, second-tier significance criteria: GWAS significance at discovery, replication P < 0.05, consistent directions of associations between discovery and replication sets, and GWAS significant at final meta-analysis; tier 3, third-tier significance criteria: suggestive significance at discovery (P < 1 × 10 −6 and P > 5 × 10 −8 ), replication P < 0.05, consistent directions of associations between discovery and replication sets, and GWAS significant at final meta-analysis.
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GenotypeTissue Expression Project (GTEx) 36 tissues and the human kidney reference described by Ko et al. 37 by using SPrediXcan 31 . We identified statistically significant GPGE associations for 1,552 genetissue pairs with SBP, 521 with DBP and 1,970 with pulse pressure ( Supplementary Table 8a -c; Supplementary Figs. 2-4 ). We identi fied 409 genes with this analysis that would not have been identified if SNPs were annotated using the nearest gene. MTHFR was the top result from SBP and showed decreasing SBP with increasing GPGE in skeletal muscle, aorta and several other tissues.
Mouse kidney single-cell sequencing analysis. Homologs of human genes identified as significant in the SPrediXcan analy sis of kidney tissue were investigated for kidney cell type-specific RNA expression by using singlecell sequencing in mouse kid , and the x axis shows the chromosomal positions. The horizontal red line represents the threshold of P = 5 × 10 −8 for genome-wide significance. SNPs in red are in previously identified loci (includes discovery only; n eff -max = 459,670 for SBP, 459,093 for DBP and 459,305 for pulse pressure), whereas SNPs in orange are in novel loci (includes discovery and replication; n eff -max = 760,226 for SBP, 767,920 for DBP and 759,768 for pulse pressure). All P values are computed for associations between genotyped or imputed SNPs and blood pressure traits as dependent variables in multivariable adjusted logistic regression models.
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NATuRe GeNeTIcS ney cells. Cells were clustered into 11 groups representing struc tural features and other cell types found in the kidney. Of the 28 genes, 16 were most expressed in one of the five tubulerelated cell types: proximal tubules, loop of Henle, distal convoluted tubules, collecting duct principal cells or collecting duct intercalated cells ( Fig. 3 ; Supplementary Table 9a -c). Crossreferencing protein expression levels in the Human Protein Atlas 38 confirmed find ings from mouse kidney, including higher expression of CDC16, SRR, SFXN2 and CLCN6 proteins in tubules than glomeruli (Supplementary Table 10 ).
Assessment of gene-drug relationships.
To better understand how genes identified in the study relate to medications, associations identified from the GPGE analyses were investigated for overlap with gene targets of known antihypertensive medications, non antihypertensive medications, and medications with adverse drug events (ADEs) for hypertension or hypotension ( Supplementary  Tables 11 -14) . A total of 2,177 tissue and bloodpressuretrait specific druggene relationships were identified in this analysis. Of these, there were 617 unique drug-gene relationships, with 175 (28.36%) with antagonistic effects. The genes PDE3A, PSMB9 and SH2B3, which are targeted by the nonantihypertensive drugs theophylline, carfilzomib and pazopanib, respectively, have ADEs of either hypotension or hyper tension and increased blood pressure with increasing GPGE. The most significant gene in SPrediXcan targeted by an antihyper tensive medication was CLCN6 (SBP β = − 2.76, P = 8.14 × 10 −45 ) in tibial artery tissue ( Supplementary Table 11 ). The most signifi cant gene in SPrediXcan with a positive effect size and that was targeted by a nonantihypertensive medication was PRKAR2B (β = 1.38, P = 1.39 × 10 −81 ) in aortic artery tissue identified from the pulse pressure analysis (Supplementary Table 12 ). The most signifi cant gene in SPrediXcan with a positive effect size and that was targeted by a drug with an ADE for hypertension was PSMB9 (pulse pressure β = 0.42, P = 7.57 × 10 −9 ) in tibial artery tissue ( Supplementary Table 13 ).
PheWAS with blood pressure genetic risk scores. To systemati cally evaluate pleiotropy between genetic predictors of blood pres sure traits and diseases throughout the phenome, we performed PheWAS using blood pressure trait-weighted genetic risk scores (wGRSs) separately in selfreported or administratively identified nonHispanic white, nonHispanic black and Hispanic individuals in the MVP. We used all known and novel common sentinel SNPs from the final metaanalysis and traitspecific weights from the UKB discovery sample to generate wGRSs for each blood pres sure trait and regressed PheWAS outcomes from MVP onto those scores, adjusted for the top ten genetic principal components. Of 1,813 phenotypes, 88 were significantly associated with any wGRSs at a Bonferronicorrected P threshold < 2.76 × 10 −5 ( Supplementary  Table 15 ). Hypertension (smallest P < 1 × 10 −305 ), essential hyper tension (smallest P < 1 × 10 −305 ) and hypertensive heart and/or renal disease (smallest P = 3.3 × 10 −173 ) were the top associations for all nine wGRSs. PheWAS associations were consistent across race and ethnic groups ( Supplementary Fig. 5 ). Associations with pheno types in the circulatory system (n = 52) accounted for > 50% of the significant results in whites. The phenotype groups with the next most abundant associations were endocrine or metabolic (n = 28), genitourinary (n = 10) and hematopoietic (n = 6).
Among significant associations, 45 were significant for all three wGRSs, 10 were significant for both SBP and DBP, and 15 were significant for both SBP and pulse pressure, demonstrating sub stantial overlap between signals captured by genetically pre dicted blood pressure traits ( Supplementary Fig. 6 ; Supplementary  Table 15 ). Thirteen associations were significant only with the pulse pressure wGRS, five of which were diabetes sequelae: ophthalmic 
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NATuRe GeNeTIcS manifestations, neurological manifestations, diabetic retinopathy, other abnormal glucose and polyneuropathy. Aortic and other aneurysms were associated only with the DBP wGRS but not with other wGRSs.
Enrichment and pathway analyses. We evaluated whether statisti cally significant genes from SPrediXcan analyses were enriched in one or more tissues. Compared with other tissues, the aorta showed the greatest evidence for enrichment of significant genes across all three traits (SBP P = 3.7 × 10 −3 ; DBP P = 5.7 × 10 −3 ; and pulse pres sure P = 1.2 × 10 −9 ; Supplementary Table 16 ). We provided senti nel SNPs from known and novel loci for each blood pressure trait (Supplementary Tables 17a-c and 18a-c) to DEPICT 39 and detected enrichment of 36 tissues across seven systems for pulse pressure (false discovery rate < 5%). The greatest enrichment was seen in arteries (P = 3.43 × 10 −10 ), and 11 of the 36 tissues are grouped in the cardiovascular system ( Supplementary Table 17c ). Geneset enrich ment of the pulse pressure GWAS results identified 574 enriched gene sets (false discovery rate < 5%); abnormal vascular smooth muscle morphology (MP:0005592; P = 1.47 × 10 −8 ) was the top gene set ( Supplementary Table 18c ). We prioritized statistically significant results from the SPrediXcan aorta tissue analyses for all three traits and investigated pathways by using Ingenuity Pathway Analysis (IPA) soft ware ( Supplementary Figs. 7-9 ). Cardiovascular disease (SBP P = 7.2 × 10 −6 ; pulse pressure P = 9.53 × 10 −4 ) and cardiovascular system development and function (SBP P = 7.7 × 10 −5 ; pulse pres sure P = 9.53 × 10 −4 ) networks were among the top enriched net works. Notable features in the SBP IPA results included the TGFβ and Notch signaling pathways ( Supplementary Fig. 7 ), whereas pulse pressure IPA results featured atherosclerosis genes including CDH13, TCF7L2, PHACTR1 and MTHFR ( Supplementary Fig. 9 ).
Convergence of evidence.
We collated evidence for genes that were associated in two or more types of investigations that inform rel evant gene targets (rare coding variants, predicted gene expression, singlecell sequencing expression enrichment and drug query) and highlighted noteworthy genes (Table 3 ). We identified 46 known and 7 novel genes satisfying this criterion, including three Mendelian hypotension or hypertension genes and 15 genes targeted by antihypertensive medications. Nine genes were expressed in murine kidney tubule cell types and 19 genes were identified in at least one aorta IPA network.
Discussion
We present results from multiomic analyses of a transethnic GWAS consortium for blood pressure traits. By incorporating large sample sizes, bioinformatics and measures of gene expression, we reinterpret the genetic architecture of blood pressure and identify tissues and anatomical features where blood pressure genes exert effects. Interrogation of gene-drug relationships and toxicities for GPGE associations provides additional evidence for known and novel blood pressure genes, and suggests genes as potential leads for drug development and repurposing potential for existing drugs. We emphasize the utility of largescale blood pressure GWAS as a requisite starting point for analyses providing insight into clinical factors, genetic etiology, pathophysiology and pharmacology of blood pressure homeostasis.
The MVP comprises US military veterans and has an over representation of male and black participants compared with the US population. We had a larger number of Hispanic participants than that in the largest previous study of blood pressure traits in that population 13 , and almost twice the number of black partici pants as that in the largest previous study of populations of African ancestry 10 . Our comparison of SNP effects on blood pressure traits demonstrated a lower correlation between race or ethnic groups than did Franceschini et al. 9 ; however, the effects that we compared were much more subtle than the first 29 blood pressure SNPs detected by Ehret et al 6 . We compared effects on clinical out comes of genetically imputed blood pressure traits in a PheWAS and observed consistent effects between racial or ethnic groups in MVP. These results support the previous observation 9 that genetic 
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NATuRe GeNeTIcS effects on blood pressure of common SNPs are consistent among populations and suggest that an increasing burden of blood pres sure-increasing alleles has a similar effect on health across white, black and Hispanic populations. Evidence from SPrediXcan and DEPICT identified arteries as the tissue type with greatest evidence for gene enrichment. These findings are in agreement with results from Warren et al. 12 showing arteries as the top tissue from a DEPICT analysis of blood pressure traits, and also with results from Gamazon et al. 40 showing aorta as the top PrediXcan tissue with highly enriched gene signals for SBP. The lack of enrichment of genes in other relevant tissues such as the kidney may be explained by the smaller sample of kidney tissues available in prediction training sets or by the finding that tissue specific gene expression is differentially enriched.
The SBP IPA analysis highlights genes linked to TGFβ and Notch signaling pathways including FURIN, GUCY1A3 (also known as GUCY1A1) and GUCY1B3 (Table 3 ; Supplementary  Fig. 7 ). GPGE of FURIN in the aorta was positively associated with SBP. This effect is likely to be mediated by furininduced activation of proTGFβ 1 to TGFβ 1, which works along with the RAS path way to increase blood pressure [41] [42] [43] [44] . Predicted expression of FES, a gene < 1 kb upstream of FURIN, is inversely associated with SBP in the aorta, coronary artery, tibial artery and kidney ( Supplementary  Table 8a ), thus suggesting the presence of two proximal blood pres sure loci with different regulatory mechanisms. Naproxen, a non steroidal antiinflammatory drug, has an inhibitory effect on FES (Supplementary Tables 12 and 13) , and hypertension is one of its known side effects 45 . Findings highlight the importance of the role of soluble guanylyl cyclase expression via the Notch signaling path way in the mouse aorta in hypertension 46 . GUCY1A3 and GUCY1B3 encode subunits of soluble guanylyl cyclase, a major nitric oxide receptor in the vascular wall [46] [47] [48] . As mediators of the vasodilatory effects of nitric oxide, increased expression of these genes predicted a decrease in SBP in aorta (Table 3 and Supplementary Table 8a ).
To understand how genetically predicted blood pressure is associated with the clinical phenome, we calculated wGRSs for each blood pressure trait and evaluated them with a PheWAS (Supplementary Table 15 ). The pulse pressure wGRS was associ ated with diabetic complications, whereas the wGRS for SBP or DBP had fewer diabetesrelated associations. Pulse pressure is an independent predictor of cardiovascular disease and incident dia betes 49, 50 . Elevated pulse pressure is a marker for arterial stiffness 51 , which is positively associated with diabetic retinopathy and neuro pathy 52 . These findings are supported by the pulse pressure IPA results, in which the top cardiovascular gene network includes at least four genes that may directly or indirectly mediate arterial stiff ness or atherosclerosis, including TCF7L2, CDH13, PHACTR1 and MTHFR ( Supplementary Fig. 9 ) [53] [54] [55] [56] [57] [58] [59] . Our finding of a positive asso ciation between the DBP wGRS and aortic and other aneurysms supports evidence from a previous study of 1.25 million individuals showing an association between DBP and aortic aneurysm 60 . Our study provides evidence for a genetic etiology of this observation.
Convergent evidence from multiple analyses identified several blood pressure genes with strong biologic importance, including PDE3A and novel genes RXFP2 and ADK. RXFP2 is a receptor for the hormone relaxin 61 , which causes vasodilation, increases cardiac output and renal perfusion, and has been evaluated in clinical trials as a treatment for acute heart failure [62] [63] [64] . RXFP2 is expressed in mul tiple tissues, and it probably underlies the multiple physiological effects of the relaxin hormone throughout the circulatory system 65 .
The product of ADK, adenosine kinase, catalyzes the transfer of γ phosphate from ATP to adenosine to form AMP and has wide spread effects on multiple systems including the cardiovascular, nervous and respiratory systems 66 . Adenosine terminates supra ventricular tachycardia involving the atrioventricular node and has been attributed to cardiac bradyarrhythmias 67, 68 . Intravenous adenosine injection in humans induces vasodilation and systemic hypotension 69 , and is the primary drug used in the treatment of Selection criteria: evidence from at least two categories (coding variant gene, S-PrediXcan gene, gene implicated in mouse kidney single-cell expression, or drug target) and from at least four analyses. Gene, gene showed enriched expression in one or more cell type in mouse kidney single-cell RNA sequencing experiment, or was significant in genetically predicted gene expression analysis for any of the 45 tissues. Novel, indicator variable denotes whether variants in a given gene region have previously been reported in genome-wide association studies of blood pressure traits. Sentinel SNPs, sentinel SNP from common or rare variant analyses from each independent locus. Nearest gene, genes that would have been identified if the nearest gene annotation strategy were used to link GWAS significant variants. CVD tissues, genes that were significantly associated with genetically predicted gene expression and blood pressure traits (using S-PrediXcan) in the following cardiovascular related tissues: heart atrial appendage, heart left ventricle, aorta, coronary artery, tibial artery, adrenal gland and kidney. Up (or down) arrow indicates a positive (or negative) association between GPGE and at least one blood pressure trait. Dash indicates that data were not significant, and x indicates that data were unavailable. A full set of tissue-specific results can be found in Supplementary Table 8a -c. Mouse kidney single-cell clusters, cell type in which specific genes were enriched in murine single-cell RNA sequencing expression analyses. 'Supplementary drug table reference' references the supplementary tables containing the gene-drug relationship. Count/drug, summarizes drugs targeting genes when the number of drugs is two or fewer, or the total number of drugs targeting the gene when the number of drugs is more than two, which were identified to interrelate with the gene from the following databases: Guide to Pharmacology Interactions, Drugbank, PharmGKB, TDG Clinical Trials, TEND and/ or ChEMBL Interactions. Aorta IPA, trait(s) for which the gene was identified in the aorta IPA network. PP, pulse pressure. a Genetically predicted expression of these genes was positively associated with pulse pressure, inversely associated with DBP and nonsignificant for SBP. b Genetically predicted expression of these genes was positively associated with DBP, inversely associated with pulse pressure and nonsignificant for SBP. c Genetically predicted expression of these genes was positively associated with DBP and inversely associated with SBP and pulse pressure. d Genetically predicted expression of these genes was positively associated with SBP and pulse pressure and inversely associated with DBP. e Targeted by an antihypertensive medication. f Mendelian gene for hypertension. g Mendelian gene for hypotension. 
NATuRe GeNeTIcS stable narrowcomplex supraventricular tachycardia 70 . It reduces blood pressure and blood pressure variability in rats, and its actions are mediated through adenosine receptors 71 . We show a positive association among GPGE of ADK and SBP and pulse pressure in aortic tissue ( Supplementary Table 8a ,c), a result consistent with the known directional effects of adenosine on blood pressure. PDE3A is targeted by a wide variety of inhibitors for indications including congestive heart failure, hypertension and heart disease. The PDE3A inhibitor theophylline, which is used to treat chronic obstructive pulmonary disease, has a hypotension ADE, in agree ment with the effects of increased gene expression in our ana lysis ( Supplementary Tables 12 and 13 ). The autosomal dominant Mendelian condition hypertension and brachydactyly syndrome (HTNB; MIM 112410) is caused by at least six distinct rare PDE3A mutations 72, 73 . HTNB features include brachydactyly type E, severe saltindependent but agedependent hypertension, increased fibro blast growth rate, neurovascular contact at the rostralventrolateral medulla, altered baroreflex blood pressure regulation and death from stroke before age 50 when untreated 74, 75 . Associations between common variants in the PDE3A locus and blood pressure have been reported previously 25, 26 .
A novel aspect of this study is the incorporation of singlecell gene expression data from cells derived from murine kidneys. We show that most blood pressure genes identified by SPrediXcan analyses in human kidneys are enriched in tubule cell types derived from mouse kidneys. This observation suggests that genes detected through GPGE associations and expressed in tubules, including SRR, ACHE, SFXN2 and CLCN6, may have a role in blood pressure regulation. Several lines of evidence implicate the SRR gene, whereas the nearest gene annotation strategy identifies SMG6 as associated with blood pressure at this locus. A SNP in SMG6, rs216172, has been associated with coronary artery disease 76 ; however, this SNP is an expression quantitative trait locus for SRR and not for SMG6 (GTEx portal). SNPs near SRR have been associated with type 2 diabetes and type 2 diabetes-mediated arterial stiffness 53 . ACHE terminates signal transduction at the neuromuscular junction by rapid hydrolysis of acetylcholine released into the synaptic cleft 77 . Inhibition of acetylcholinesterase is an effective treatment for orthostatic hypotension, especially in people with supine hyperten sion 78 . Dimetacrine, a tricyclic antidepressant, and decamethonium, a muscle relaxant, have inhibitory effects on ACHE and are not cur rently prescribed as antihypertension medications.
This work helps to clarify the complex MTHFR locus by provid ing unique tissuespecific evidence for several genes in the region in relation to blood pressure 79, 80 . In addition to MTHFR, our study provides evidence for the role of NPPA (novel missense variant; Table 2 ), NPPB (GPGE association with SBP and pulse pressure in the left ventricle; Supplementary Table 8a and 8c) and CLCN6 (inverse association in the kidney SPrediXcan and enrichment in mouse kidney; Supplementary Tables 8a-c and 9a-c) in blood pres sure. NPPA and NPPB are exclusively expressed in the heart, have biological functions including natriuresis, diuresis, vasorelaxation, inhibition of renin and aldosterone secretion, and have a key role in cardiovascular homeostasis 81 . GPGE of CLCN6, a putative chloride antiporter 82 , was consistently associated with SBP, DBP and pulse pressure. CLCN6 is targeted by the antihypertensive medication chlorthalidone, and NPPB is targeted by the antihypertensive medi cation carvedilol ( Supplementary Table 11 ). Findings for this locus show that effects of multiple associated genes from the same locus may vary by tissue type, and several nearby genes with very different biological functions may jointly contribute to the trait of interest.
In conclusion, we applied multiple postGWAS analyses to identify genes with effects on blood pressure regulation. We report hundreds of novel SNPs and genes, including several with strong biological plausibility, and tissuespecific gene associations with direc tions of effect. We provide insight into the natural experiments of gene regulation and direct perturbation of proteins by muta tion with regard to effects on blood pressure, enhancing the biological understanding of blood pressure traits. Our study identifies a refined set of genes that often have coordinated expres sion across multiple tissues with potential relevance to blood pressure traits, and these genetissue pairs are prime candidates for causal investigation. 
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Methods
We conducted a multistage GWAS of common and rare variants in > 750,000 participants. We then performed additional bioinformatics analyses of GPGE for blood pressure traits, evaluated cell types in which associated genes are expressed, performed a phenomewide association study of genetic risk scores for blood pressure traits from the electronic health records of MVP participants and screened known drugs to evaluate potential for repurposing and validate observed associations. A flow chart for analyses is presented in Fig. 1 .
Discovery cohorts. The Million Veteran Program. The MVP is a large cohort of fully consented participants who were recruited from the patient populations of 63 Department of Veterans Affairs (VA) medical facilities. The MVP is recruited at VA hospitals from men and women who are veterans of the US armed forces. It is enriched with AfricanAmerican and Hispanic participants compared with the general US population, and males are overrepresented. Across race groups, the average age ranged between 49 for Asian and 61 for black participants (Supplementary Table 1 ). Average body mass index (BMI) ranged between 27.8 for Asians and 30.9 for Native Americans. The proportion of males ranged between 87% for Native Americans and 93% for whites. Average SBP ranged between 132 mm Hg for Asians and 140 mm Hg for blacks, average DBP ranged between 81 mm Hg for Asians and 85 mm Hg for Blacks, and average pulse pressure ranged between 51 mm Hg for Asians and 57 mm Hg for whites. The proportion of participants on an antihypertensive drug at the time of blood pressure measure ranged between 31% for Asians and 53% for blacks.
Recruitment began in 2011 and is conducted in person, initiated by an invitation letter and completed by participants answering baseline and lifestyle questionnaires, providing a blood sample, providing access to medical records and giving permission for recontact. Consent to participate is provided after counseling by research staff and mailing of informational materials. All documents and protocols are approved by the VA Central Institutional Review Board. Blood samples are collected by phlebotomists and banked at the VA Central Biorepository in Boston. Genotyping was conducted using a customized Affymetrix Axiom Biobank Array chip with content added to provide coverage of African and Hispanic haplotypes, as well as markers for common diseases in the VA population. Researchers are provided with deidentified data, and do not have the ability or authorization to link these details with a participant's identity. MVP genotype quality control. Blood samples drawn from consenting MVP participants were shipped to the Central Biorepository in Boston, where DNA was extracted and shipped to two external centers for genotyping on an Affymetrix Axiom Biobank array designed specifically for the MVP. The MVP genomics working group applied standard quality control and genotype calling algorithms to the data in batches using the Affymetrix Power Tools Suite (v1.18). Standard quality control pipelines were used to exclude duplicate samples, samples with more heterozygosity than expected, samples with an excess (> 2.5%) of missing genotype calls and samples with discordance of genetically inferred sex versus selfreport. We excluded related individuals (halfway between second and third degree relatives or closer) as measured by the KING software 84 . Before imputation, variants that were poorly called or that deviated from their expected allele frequency based on reference data from the 1000 Genomes Project 85 were excluded. After prephasing using EAGLE v2 (ref. 86 ), genotypes from the 1000 Genomes Project 85 phase 3, version 5 reference panel were imputed into MVP participants via Minimac3 software 87 . Principal component analysis was performed using FlashPCA 88 to generate the top ten genetic principal components explaining the greatest variability. Race and ethnicity. Information on race (whites, blacks, Asians and Native Americans) and ethnicity (Hispanic, yes or no) was obtained based on selfreport through centralized VA data collection methods using standardized survey forms, or through the use of information from corporate data warehouse or Observational Medical Outcomes Partnership data, when information from selfreport survey was missing. Race and ethnicity categories were then merged to form the following race or ethnicity variables: nonHispanic whites (whites), nonHispanic blacks (blacks), nonHispanic Asians (Asians), nonHispanic Native Americans (Native Americans) and Hispanics. Individuals for whom race and ethnicity could not be assigned due to conflicting records or missing data were categorized as unknown. Before analysis quality control, there were 15,710 veterans with unknown status for race or ethnicity. For these individuals, we used a Kmeans clustering approach in R (McQueen algorithm) with the top ten genetic principal components as input. To obtain the most reliable cluster designations for the missing data, the Kmeans approach was applied to the maximum available samples: the 1000 Genomes reference populations and all individuals for whom principal components were available regardless of whether race or ethnicity designations were unknown. Kclusters were optimized by testing values K = 2 through K = 10. K = 4 was chosen as the optimal value, as visual examination of these clusters most closely corresponded to whites (n = 5,265), blacks (n = 4,671), Asians (n = 3,936) and Hispanics (n = 1,838). MVP blood pressure phenotypes. We selected adults (age ≥ 18), used the median eligible nonEmergency Department outpatient-measured SBP in the entire available electronic health record (EHR) and used the corresponding DBP from this measure. In individuals for which the median value was observed at multiple clinical encounters on distinct dates, we used the earliest of those measures to identify the DBP, age, BMI and antihypertensive treatment status of the individual at that time. Measures were ineligible if they occurred at or after an International Classification of Diseases, 9th Revision (ICD9) code from the groups 585 (chronic kidney disease), 405 (secondary hypertension) or 428 (heart failure). If pain scores were available, blood pressure measures taken during encounters when a pain score was ≥ 5 was recorded were also ineligible, because severe pain can elevate blood pressure 89, 90 . For measures taken while a subject was on an antihypertensive medication we added 15 mm Hg to SBP and 10 mm Hg to DBP 8, 91 . MVP analysis. For the MVP GWAS, we performed linear regression association tests with additive models for untransformed blood pressure traits, after adjusting for medication use. We adjusted linear regression models analyzing SNP associations for age at blood pressure measure, age 2 , sex, BMI measured within 1 year of blood pressure measure and the top 10 genetic principal components in analyses. All primary analyses for the MVP were conducted by either strata of administratively assigned race or ethnicity or by their empirically designated clusters. All regression based analyses were conducted in SNPTESTv2.5.4beta 92 . Analyses were limited to genotyped and imputed variants with SNPTEST Info scores of ≥ 0.4, with HardyWeinberg equilibrium P > 5 × 10 −8 for common variant analysis (minor allele frequency > 0.1). Analyses of rare variants, SNPs with MAF ≤ 1%, were restricted to variants with an effective minor allele count (SNPTEST Info score multiplied by minor allele count) of ≥ 10 in each analysis subcohort.
The UK Biobank. Summary statistics from the analysis of the interim data from the UKB were used in our metaanalysis. These results have been reported by Warren et al 12 . Briefly, following central and studyspecific quality control protocols, 140,886 empirically classified white individuals were analyzed for SBP, DBP and pulse pressure traits. Blood pressure measures were averaged over two measures and adjusted for medication use by adding 15 and 10 mm Hg to SBP and DBP, respectively. Linear models were adjusted for the top ten principal components of ancestry, age, agesquared, sex, an indicator for genotyping platform and BMI.
Meta-analysis of discovery data sets. Inversevariance weighted fixedeffects meta analysis of common variants across MVP subsets and summary statistics from UKB was performed by using METAL software. Genomic inflation factor were calculated, and λ GC values for SBP, DBP and pulse pressure were 1.195, 1.149 and 1.171, respectively for the discovery from MVP, 1.303, 1.315 and 1.270 for the discovery from UKB, and 1.275, 1.140 and 1.244 in the overall discovery analysis ( Supplementary Fig. 10 ). Subsequently, we used the LD score regression approach 93 to ascertain whether inflation was due to residual population stratification or polygenicity. Calculation of the intercept in the MVP discovery analysis data set of white participants was 1.05 (s.e.m. = 0.01), 1.03 (s.e.m. = 0.01) and 1.04 (s.e.m. = 0.01) for SBP, DBP and pulse pressure, respectively, suggesting that little of the observed inflation in the λ GC is due to population stratification.
Selection of SNPs for replication. Common variants. For common variants, we considered for followup SNPs in loci that did not overlap with previously reported loci according to both an LD threshold of r 2 ≤ 0.1 and a 1 Mb interval. We obtained a list of these SNPs with P < 1 × 10 −6 for any of the three blood pressure traits, a MAF ≥ 1% and concordant directions of effect between UKB and MVP.
In silico replication summary statistics were provided for 942 SNPs by the ICBP 25 after metaanalysis of 77 individual participating cohorts for a total maximum of 299,024 individuals who were genotyped and analyzed according to studyspecific protocols. Additional replication results were provided from Vanderbilt University's BioVU EHRlinked biorepository, including genotypes from the MEGA array and phenotype data from 17,277 participants. Discovery and replication data were combined using fixedeffects inversevariance weighted metaanalysis implemented in METAL 94 . Rare variants. We conducted an in silico replication analysis of 18 rare exonic SNPs from our discovery analysis in 417,143 participants from BPICE. SNPs were chosen for replication if they had a discovery P < 1 × 10 −6 and a MAF < 1%.
BPICE used the exome array and did not have genomewide coverage of rare variants. Therefore, we also pursued replication using the full release of the UKB data to capture nonexonic rare variation. Because of the inclusion of UKB data in the discovery set, for the second analysis we sought replication from variants suggestive (P < 1 × 10 −6 ) only in MVP cohorts following metaanalysis as described above. Some 1,066 rare variants with P < 1 × 10 −6 for any of the three phenotypes were selected for replication in 458,577 participants from UKB. Additional replication was provided by BioVU MEGA, and all data were metaanalyzed by using fixedeffects metaanalysis in METAL 94 .
Classifying results by evidence for association. For results that reached statistical significance of P ≤ 5 × 10 −8 after final metaanalysis, and that had consistent direction of effect between discovery and replication stages, we established three tiers of evidence, which are annotated in results tables ( Supplementary Table 3a -c):
(i) Genomewide significance in the discovery stage, Bonferronicorrected significance in replication and consistent traitspecific direction of effect across stages.
(ii) Genomewide significance in the discovery stage, P ≤ 0.05 in the replication stage and consistent traitspecific direction of effect across stages.
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(iii) Variants had P < 1 × 10 −6 and P > 5 × 10 −8 in the discovery stage, had P < 0.05 in the replication stage, had consistent traitspecific direction of effect across stages and were genomewide significant after final analysis.
Conditional analysis. For conditional analysis of common variants we used two parallel approaches implemented in Genomewide Complex Traits Analysis (GCTA) software 95 . Details are described in the Supplementary Note.
Proportion of variance explained. We approximated the proportion of blood pressure trait-specific variance explained in the transethnic metaanalysis by all independent sentinel SNPs (novel and known) and novel SNPs separately. Variance explained by each SNP was first estimated by the following equation:
The sum of the variances of the independent sentinel SNPs for common variants provided estimates of the proportion of variance explained for all SNPs and novel SNPs for each of the blood pressure traits. The transformation of the relationship between tstatistic and r 2 to χ 2 statistic to r 2 is described in the Supplementary Note.
Genetic risk score construction. We constructed a genetic risk score (GRS) for each blood pressure trait by calculating a linear combination of weights derived from the 140,886 participants from the UKB common variant analysis and sentinel SNPs at each statistically significant locus observed in the MVP. wGRSs were constructed for selfreported or administratively assigned nonHispanic whites, blacks and Hispanics in the MVP.
Phenome-wide association study analysis. We performed a PheWAS 96 of GRS for each blood pressure trait in MVP whites (n max = 188,088), blacks (n max = 52,530) and Hispanics (n max = 16,735), leveraging the diverse nature of MVP as well as the full catalog of ICD9 diagnosis codes. We used logistic regression to separately model up to 1,813 PheWAS traits as a function of the three GRSs, adjusted for age, agesquared, sex, BMI and ten principal components. We report the results from these analyses as odds ratios, in which the estimate is the average change in odds of the PheWAS trait per weighted blood pressure-increasing allele. Interpretation of results was limited to phenotypes with 25 or more cases. Multiple testing thresholds for statistical significance were set to P ≤ 2.75 × 10 −5 (0.05/1,813). All PheWAS analyses were conducted by using the R PheWAS package 97 . Effect estimates based on significant PheWAS results from any one or more of the analyses were then compared among whites, blacks and Hispanics to report Pearson's correlations (r 2 ) for each pair per trait ( Supplementary Fig. 5 ).
S-PrediXcan analysis.
Genetically predicted gene expression was evaluated for the common variant subset with SPrediXcan 31 , a genelevel approach that estimates the genetically determined component of gene expression in a given tissue and tests it for association with SNPlevel summary statistics. We used all three blood pressure metaanalysis results for common variants and 44 tissues from GTEx 36 for this analysis, as well as the collection of kidney reference data recently described by Ko et al. 37 , incorporating covariance matrices developed for European populations (1000 Genomes), as the majority of samples were European in origin.
Evaluation of kidney loci in mouse kidneys. For the genes implicated by the SPrediXcan analysis as having associated expression in the kidney, we evaluated homologous genes in the singlecell atlas of the mouse kidney, in which expression levels are measured by singlecell RNA sequencing across 57,979 total mouse kidney cells from seven healthy mice 83 . This enabled us to observe what cell types in the mammalian kidney express the genes where there was evidence for association between expression and blood pressure traits. After quality filtering steps, a single cellgene matrix containing the unique molecular identifier counts for 43,745 cells and 16,273 transcripts was generated from seven normal mouse kidneys by using 10x Chromium Single Cell solution 83 . Mouse homologs of the target human genes identified by the SPrediXcan analysis were found by using Ensembl BioMart. Genes that expressed < 5% of the cell clusters were excluded from analysis. To calculate the average expression level for each cluster, a zscore of unique molecular identifier count was first obtained for every single cell. Then we calculated the mean zscores for individual cells in the same cluster, thus resulting in a zscore for each gene and each cell cluster.
Evaluation of drug classes for genes with associations with gene expression.
To better understand the performance of the SPrediXcan method, identify genes that could be leads for drug development and identify druggene pairs that might be leads for repurposing, we made three comparisons among significant associations from SPrediXcan analyses: (i) we identified all SPrediXcan genes targeted by an antihypertensive drug to validate associations and identify the most credible genes in regions with many associations; (ii) we listed candidate genes that might be leads for novel inhibitory antihypertensive therapies by considering genes with GPGE effects on blood pressure that are also targeted by a nonantihypertensive drug; and (iii) for genes that might be leads for developing novel treatments and drugs with repurposing potential, we reported gene-drug pairs for significant SPrediXcan genes that are not targeted by an antihypertensive drug but are targeted by a drug with a toxicity that involves hypertension or hypotension.
A list of medications with a primary indication for hypertension and a list of medications with ADEs of hypertension or hypotension were created by using SIDER 98 and the DEB2 database 99 . Gene targets for antihypertension medications, medications targeting genes significant in SPrediXcan analyses with positive effect sizes and medications targeting genes mapped from significant GWAS signals were queried by using DGIdb 100 . Primary indications for medications targeting genes significant in SPrediXcan analyses with positive effect sizes were compiled by using the BIDD TTD database 101 .
To identify genes that are attractive leads for novel inhibitory drugs, we report significant SPrediXcan genes with a positive effect size (i.e., for which increasing gene expression is associated with an increase in one or more blood pressure traits) that are targeted by a nonantihypertensive medication without an indication of ADEs for hypertension or hypotension. This list thereby represents a set of genes that both are likely to be involved in blood pressure regulation in one or more tissues and can be targeted by drugs. Known targets for antihypertensive drugs found to be significant by SPrediXcan and a summary of the most significant SPrediXcan results across tissues and blood pressure traits are presented in Supplementary Table 11 . Significant SPrediXcan genes that are associated in any tissue and that are targeted by a nonhypertension drug with no ADE for hypertension or hypotension are presented in Supplementary Table 12 .
We report another group of genes that might be attractive for treatment development on the basis of being both associated with blood pressure traits and targeted by nonantihypertensive drugs that feature an ADE of either hypotension or hypertension. These genedrug pairs may be leads for modification of drug molecules, modification of dosing or delivery strategies, or potential gene targeting by new treatments. Genes that were found to be significant by SPrediXcan, that are targeted by a drug, and that have an ADE involving hypertension or hypotension are presented in Supplementary Table 13 . Gene-drug relationships for all genes mapped from significant association signals are presented in Supplementary Table 14 .
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Data analysis
Several data-analysis software programs were used for this study and are included in the manuscript under the URLs section as well. Names of these software programs and links are provided here as well:
